Published: 19 April 2024
Author(s): Nicole Felix, Paula C. Nogueira, Isadora M. Silva, Thomaz Alexandre Costa, Carlos Alberto Campello, Carlos Stecca, Renato D. Lopes
Issue: May 2024
Section: Original Article

Cancer and cardiovascular disease are two leading causes of mortality worldwide, and cancer survivors have an increased cardiovascular risk due to shared risk factors with cardiovascular disease and the potential for cardiotoxicity related to cancer therapies, now referred to as cancer therapy-related cardiovascular dysfunction (CTRCD) [1]. CTRCD is a main cause of chemotherapy discontinuation, morbidity, and mortality in this patient population [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.